SCHEMBL16710140

SCHEMBL16710140

O=C(c1csc(CN(Cc2cccc(C(F)(F)F)c2)Cc2ccc3c(c2)OCO3)n1)N1CCN(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
LMNA P02545 7/20 0.50
HTT P42858 4/20 0.50
MAPK1 P28482 4/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NR1H4 Q96RI1 1/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 4/20 0.44
THRB P10828 1/20 0.43
KMT2A Q03164 5/20 0.43
TSHR P16473 4/20 0.43
MEN1 O00255 3/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.42
SCD5 Q86SK9 2/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16710104 0.96 MAPT (0.46) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL16710135 0.94 NPSR1 (0.49) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL18940547 0.92 TSHR (0.49) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL16710037 0.91 NR1H4 (0.46) MAPTLMNANR1H4KMT2ATSHR
SCHEMBL16706784 0.91 LMNA (0.46) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL18938821 0.91 NR1H4 (0.55) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL16706870 0.91 NR1H4 (0.48) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL16706820 0.91 NR1H4 (0.43) MAPTLMNAHTTMAPK1SMN1; SMN2
SCHEMBL16710099 0.91 NR1H4 (0.45) LMNANR1H4KMT2ATSHRMEN1
SCHEMBL16710059 0.90 NR1H4 (0.43) MAPTLMNAHTTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 US disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 MAPT 1807/4885LMNA 280/4885HTT 4342/4885
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 MAPT 1886/4885LMNA 214/4885HTT 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.